# A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients

> **NCT01628965** · PHASE2,PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 143 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** SPM 962

## Key facts

- **NCT ID:** NCT01628965
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2014-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01628965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01628965, "A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01628965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*